Abstract
Introduction: Esculentoside A (EsA) is one of the main components of the traditional Chinese medicine Phytolacca esculenta. The possible mechanism of action of EsA in the treatment of lupus nephritis (LN) was explored by observing the effects of EsA on CD19+ IL-35+regulatory B (IL-35+Breg) cells. Methods: Twenty-four MRL/lpr mice were randomly divided into control, EsA, and EsA+IL-12p35 antibody groups. Mice were administered the respective treatments intraperitoneally once a day for 4 weeks. The urine protein/creatinine ratio (UPCR) and blood creatinine (Cr) and IL-35, IL-10, and IL-17 expression levels were measured. Body and spleen weight were measured to calculate the splenic index (SI). Flow cytometry was performed to determine the proportion of CD19+ IL-35+ Breg cells in the spleen. Hematoxylin-eosin and PASM-Masson staining of renal tissues were performed, and the “Austin” acute index (AI) system for LN was determined. Results: The most severe conditions were seen in mice in the control group, with the highest UPCR, Cr, and IL-17 levels and SI and AI scores; the most severe renal histopathology, and the lowest proportion of CD19+ IL-35+ Breg cells and IL-35 and IL-10 levels. This was followed by the EsA+IL-12p35 antibody group. The EsA group had the lowest UPCR, Cr, and IL-17 levels and SI and AI scores; the mildest renal lesions; and the highest proportion CD19+ IL-35+ Breg cells and IL-35 and IL-10 levels. Conclusion: EsA delayed the progression of LN by promoting the proliferation of CD19+ IL-35+ Breg cells, upregulating the expression of IL-35, and decreasing the secretion of IL-17.
Journal Section:
Experimental Immunology – Research Article
References
1.
Feng
Y
, Yang
M
, Wu
H
, Lu
Q
. The pathological role of B cells in systemic lupus erythematosus: from basic research to clinical
. Autoimmunity
. 2020
;53
(2
):56
–64
. 2.
Barnas
JL
, Looney
RJ
, Anolik
JH
. B cell targeted therapies in autoimmune disease
. Curr Opin Immunol
. 2019
;61
:92
–9
. 3.
Iwata
Y
, Matsushita
T
, Horikawa
M
, Dilillo
DJ
, Yanaba
K
, Venturi
GM
, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells
. Blood
. 2011
;117
(2
):530
–41
. 4.
Liu
J
, Chen
X
, Hao
SN
, Zhao
H
, Pang
L
, Wang
LN
, et al. Human chorionic gonadotropin and IL-35 contribute to the maintenance of peripheral immune tolerance during pregnancy through mediating the generation of IL-10+ or IL-35+ Breg cells
. Exp Cell Res
. 2019
;383
(2
):111513
. 5.
Tong
ZL
, Ye
Y
, Zhang
N
, Yin
WL
, Li
Y
. Advances in the study of the role of interleukin-10 in a variety of diseases
. Chin J Gerontol
. 2018
;22
:5590
–3
.6.
Dambuza
IM
, He
C
, Choi
JK
, Yu
CR
, Wang
R
, Mattapallil
MJ
, et al. IL-12p35 induces expansion of IL-10 and IL-35-expressing regulatory B cells and ameliorates autoimmune disease
. Nat Commun
. 2017
;8
(1
):719
. 7.
Wang
T
, Mei
Y
, Li
Z
. Research progress on regulatory B cells in systemic lupus erythematosus
. BioMed Res Int
. 2019
;2019
:1
–7
. 8.
Slawek
A
, Lorek
D
, Kedzierska
AE
, Chelmonska-Soyta
A
. Regulatory B cells with IL-35 and IL-10 expression in a normal and abortion-prone murine pregnancy model
. Am J Reprod Immunol
. 2020
;83
(3
):e13217
. 9.
Ye
C
, Yano
H
, Workman
CJ
, Vignali
DAA
. Interleukin-35: structure, function and its impact on immune-related diseases
. J Interferon Cytokine Res
. 2021
;41
(11
):391
–406
. 10.
Wang
RX
, Yu
CR
, Dambuza
IM
, Mahdi
RM
, Dolinska
MB
, Sergeev
YV
, et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease
. Nat Med
. 2014
;20
(6
):633
–41
. 11.
Ye
Z
. Study on the underlying mechanisms of Breg cells in systemic lupus erythematosus and their relationship
. Jilin University
; 2021
.12.
Zhao
M
, Zhu
GJ
, Zhou
L
. Serum IL-17 and IL-35 levels in patients with systemic lupus erythematosus and their correlations with renal damage
. J Tianjin Med Univ
. 2019
;25
(04
):359
–62
.13.
He
D
. Study on the serum expression levels of interleukin-35 and interleukin-17 in patients with lupus nephritis [D]
. Jilin University
; 2018
.14.
Cai
Z
, Wong
CK
, Dong
J
, Chu
M
, Jiao
D
, Kam
NW
, et al. Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)/lpr mice
. Clin Exp Immunol
. 2015
;181
(2
):253
–66
. 15.
Song
M
, Ma
X
. The immunobiology of interleukin-35 and its regulation and gene expression
. Adv Exp Med Biol
. 2016
;941
:213
–25
. 16.
17.
Koga
T
, Ichinose
K
, Kawakami
A
, Tsokos
GC
. Current insights and future prospects for targeting IL-17 to treat patients with systemic lupus erythematosus
. Front Immunol
. 2020
;11
:624971
. 18.
Richter
P
, Macovei
LA
, Mihai
IR
, Cardoneanu
A
, Burlui
MA
, Rezus
E
. Cytokines in systemic lupus erythematosus-focus on TNF-α and IL-17
. Int J Mol Sci
. 2023
;24
(19
):14413
. 19.
Ye
Z
, Jiang
Y
, Sun
D
, Zhong
W
, Zhao
L
, Jiang
Z
. The plasma interleukin (IL)-35 level and frequency of circulating IL-35+ regulatory B cells are decreased in a cohort of Chinese patients with new-onset systemic lupus erythematosus
. Sci Rep
. 2019
;9
(1
):13210
. 20.
Pan
C
, Zhang
C
, Li
Y
, Cao
J
, Liang
SW
, Fang
HC
, et al. Studies related to the involvement of EsA in improving intestinal inflammation in acute pancreatitis via the NF-κB pathway
. Mediators Inflamm
. 2024
;2024
:9078794
. 21.
Sun
G
, Yang
W
, Zhang
Y
, Zhao
M
. Esculentoside A ameliorates cecal ligation and puncture-induced acute kidney injury in rats
. Exp Anim
. 2017
;66
(4
):303
–12
. 22.
Tang
JY
, Dong
Y
, Zhang
XG
, Xiao
H
, Zhang
W
, Xu
LJ
. Influence of esculentoside A on activation of ERK1/2-AP-1 pathway of glomerular mesangial cell induced by IL- 1
. Chongqin Med J
. 2017
;46
(16
):2183
–6
.23.
Ma
HL
, Zhang
XZ
, Zhang
XG
. The therapeutic effect of Esculentoside A on BXSB lupus nephritis mice
. Guangdong Med J
. 2011
;32
(12
):1540
–2
.24.
Ma
HL
, Zhang
XG
, Yang
D
, Meng
LG
. The effect of Esculentoside A on apoptosis in BXSB mice with lupus nephritis
. Mod J Integrated Traditional Chin West Med
. 2015
;24
(09
):927
–9
.25.
Tang
JY
, Zhang
W
, Zhang
XG
. Effect of esculentoside A on the differentiation of CD4+T cells to Th17
. Basic Clin Med
. 2019
;39
(12
):3
.26.
Jones-Bolin
S
. Guidelines for the care and use of laboratory animals in biomedical research
. Curr Protoc Pharmacol
. 2012
; Appendix 4:Appendix 4B. 27.
Jin
XK
, Li
WD
. Recent research on murine models of spontaneous lupus
. Chin Pharmacol Bull
. 2013
;29
(10
):1342
–4
.28.
Hou
LF
, He
SJ
, Li
X
, Yang
Y
, He
PL
, Zhou
Y
, et al. Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses
. Arthritis Rheum
. 2011
;63
(8
):2445
–55
. 29.
Yuan
ST
, Wang
ZJ
, Cheng
M
. Research progress of traditional Chinese medicine Phytolacca esculenta (III)
. J Chin Med Mater
. 1991
(4
):42
–4
.30.
Kuang
SS
, Yang
L
, Yan
JR
, Tan
QY
, Dai
LL
, Tang
XJ
. Mechanisms of immune action in MRL/lpr mice with systemic lupus erythematosus
. Chinese J Comparative Med
. 2018
;28
(04
):38
–42
.31.
Giuffrè
M
, Macor
D
, Masutti
F
, Abazia
C
, Tinè
F
, Bedogni
G
, et al. Spleen Stiffness Probability Index (SSPI): a simple and accurate method to detect esophageal varices in patients with compensated liver cirrhosis
. Ann Hepatol
. 2020
;19
(1
):53
–61
. 32.
Catalán
D
, Mansilla
MA
, Ferrier
A
, Soto
L
, Oleinika
K
, Aguillón
JC
, et al. Immunosuppressive mechanisms of regulatory B cells
. Front Immunol
. 2021
;12
:611795
. 33.
Sawant
DV
, Hamilton
K
, Vignali
DA
. Interleukin-35: expanding its job profile
. J Interferon Cytokine Res
. 2015
;35
(7
):499
–512
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
